The E2F transcription factors mediate the activation or repression of key cell cycle regulatory genes under the control of the retinoblastoma protein (pRB) tumor suppressor and its relatives, p107 and p130. Here we investigate how E2F4, the major "repressive" E2F, contributes to pRB's tumor-suppressive properties. Remarkably, E2F4 loss suppresses the development of both pituitary and thyroid tumors in Rb ؉/Ϫ mice. Importantly, E2F4 loss also suppresses the inappropriate gene expression and proliferation of pRB-deficient cells. Biochemical analyses suggest that this tumor suppression occurs via a novel mechanism: E2F4 loss allows p107 and p130 to regulate the pRB-specific, activator E2Fs. We also detect these novel E2F complexes in pRB-deficient cells, suggesting that they play a significant role in the regulation of tumorigenesis in vivo.
Introduction
teins, that also includes p107 and p130 (reviewed by Trimarchi and Lees, 2002) . p107 and p130 share many The retinoblastoma protein (pRB) was the first identified tumor properties with pRB: they bind to E2F in vivo, inhibit E2F transuppressor, and it is mutated in approximately one third of all scriptional activity, and recruit HDACs to mediate the active human tumors. pRB blocks cells in G1 by inhibiting the activity repression of E2F-responsive genes. However, there are draof a cellular transcription factor, E2F, that controls the expresmatic differences in the tumor-suppressive properties of the sion of key components of the cell cycle and DNA replication individual pocket proteins (reviewed by Mulligan and Jacks, machinery (reviewed in Trimarchi and Lees, 2002) . 1998). Inheritance of a single Rb mutant allele predisposes both pRB regulates E2F through two distinct mechanisms. First, its mice and humans to tumors with 100% penetrance. The tumors association is sufficient to block E2F transcriptional activity.
consistently lose the wild-type Rb allele, confirming that pRB Second, the pRB-E2F complex can recruit histone deacetylases behaves as a classical tumor suppressor. In contrast, the loss (HDACs) to the promoters of E2F-responsive genes and thereby of p107 and/or p130 does not appear to promote tumorigenicity actively repress their transcription. Cell cycle entry requires the in mice or cells . Yet phosphorylation of pRB and its subsequent dissociation from there is growing evidence that mutation of p107 and/or p130 E2F. This phosphorylation is mediated by cell cycle-dependent promotes tumor formation when pRB is also inactivated. This kinase complexes, cyclin D-CDK4/6, and cyclin E-CDK2. Imporis exemplified by Rb
;p107 Ϫ/Ϫ chimeric mice, which detantly, tumors that retain wild-type pRB almost always carry velop an additional tumor type, retinoblastoma, compared activating mutations in cyclin D1 or CDK4 or inactivating mutato Rb Ϫ/Ϫ chimeras (Robanus-Maandag et al., 1998) , and tions in the cdk4 inhibitor, p16 (reviewed by Bartek et al., 1996 ; Rb Ϫ/Ϫ ;p107
;p130 Ϫ/Ϫ mouse embryonic fibroblasts (MEFs), Sherr, 1996) . This suggests that the functional inactivation of which are more tumorigenic than Rb Ϫ/Ϫ controls (Dannenberg pRB, and the resulting deregulation of E2F, is an essential step et al., 2000; Sage et al., 2000) . Biochemical and mechanistic in tumorigenesis.
pRB belongs to a family of proteins, called the pocket prostudies in cells deficient for different pocket protein family mem-
S I G N I F I C A N C E
Understanding how the E2F and pRB family members contribute to the regulation of tumorigenesis is a key goal. Our finding of tumor suppression in the Rb , and Rb Ϫ/Ϫ cells strongly suggests that tumor formation is critically and exclusively dependent upon the inactivation of pRB, rather than p107 or p130, because it triggers the release of the normally pRB-specific, activator E2Fs. However, p107 and p130 assume significant tumorsuppressive properties in pRB-deficient cells because they can substitute for pRB in the regulation of these activator E2Fs. This model suggests a novel strategy for the generation of chemotherapeutics that would act by increasing the available pools of p107 and p130.
bers should help to identify the critical, tumor suppressive funcfor the repressive pRB-E2F complexes in tumor suppression. Indeed, numerous overexpression studies have led to the contion(s) of pRB.
To date, eight genes have been identified as components clusion that regulation of E2F-responsive genes, and therefore cell cycle entry, is largely controlled by the repressive, and not of the E2F transcriptional activity (reviewed by . These genes have been divided into two distinct activating, E2Fs (Dahiya et al., 2001; Zhang et al., 1999 Zhang et al., , 2000 .
In this study, we use Rb;E2f4 compound mutant mice to investigroups: the E2fs (E2f1 through E2f6) and the DPs (DP1 and DP2). The protein products from these two groups heterodimerize to gate whether repressive E2F complexes contribute to tumor suppression. This analysis shows that the absence of E2F4 give rise to functional E2F activity (Bandara et al., 1993; Helin et al., 1993; Krek et al., 1993) . The functional specificity of the suppresses the formation of pRB-deficient tumors by promoting the formation of novel complexes between the activating E2Fs E2F-DP complex is primarily determined by the identity of the E2F subunit. The pocket protein binding E2Fs can be divided and p107 and p130 as well as correcting inappropriate target gene expression and cell growth. Most significantly, these data into two subgroups that appear to have opposing roles in vivo (reviewed by Trimarchi and Lees, 2002) .
provide support for a model in which pocket proteins function as tumor suppressors by controlling activator E2Fs rather than The first E2F subgroup includes E2F1, 2, and 3. These E2Fs play a key role in promoting the activation of E2F-responsive by forming repressive E2F complexes. genes, and thereby cell cycle entry. Chromatin immunoprecipitation (ChIP) experiments confirm that these E2Fs associate Results with the promoters of known target genes coincident with their activation in late G 1 (Rayman et al., 2002; Takahashi et al., 2000) .
Loss of E2F4 extends lifespan and alters tumorigenesis in Rb mutant mice MEFs lacking E2F3 or E2F1, E2F2, and E2F3 exhibit reduced E2F target gene expression and significant proliferative defects Overexpression studies strongly suggest that the repressive E2F-pocket protein complexes play a critical role in controlling Wu et al., 2001) . Furthermore, the ectopic expression of E2F1, 2, or 3 is sufficient to induce quiescent the expression of E2F-responsive genes. Given this finding, we wished to establish whether these repressive E2F-pocket cells to initiate E2F-responsive gene expression and cell cycle re-entry (DeGregori et al., 1997; Lukas et al., 1996) . Importantly, protein complexes contribute to tumor suppression. E2F4 is the major repressive E2F in vivo, accounting for the majority of the these so-called "activator" E2Fs are specifically regulated by pRB but not by p107 or p130 in vivo (Moberg et al., 1996) . endogenous pRB-, p107-and p130-associated E2F activity. Thus, if the repressive E2F complexes are important, E2F4 loss E2F4 and E2F5 represent the second E2F subgroup. The transcriptional properties of these E2Fs are largely determined should exacerbate the formation of pRB-deficient tumors. To test this hypothesis, we intercrossed Rb and E2f4 mutant mouse by their subcellular localization (Gaubatz et al., 2001; Magae et al., 1996; Muller et al., 1997; Verona et al., 1997) . The endogestrains with the same C57BL/6 X 129/Sv mixed background. We then compared the lifespan and tumor phenotype of Rb ϩ/Ϫ , nous E2F4-DP and E2F5-DP complexes are localized in the cytoplasm and are therefore unable to contribute to the activaRb ϩ/Ϫ ;E2f4 ϩ/Ϫ and Rb ϩ/Ϫ ;E2f4 Ϫ/Ϫ littermates. The phenotype of the Rb ϩ/Ϫ mice was entirely consistent tion of E2F-responsive genes. However, pocket protein binding enables the nuclear localization of E2F4 and E2F5. As a result, with previous studies (reviewed by Mulligan and Jacks, 1998) . All mice died between 8.5 and 13.9 months of age ( Figure 1A ). E2F4 and E2F5 appear to be primarily involved in the active repression of E2F-responsive genes. E2F4 associates with pRB, Histological examination confirmed that the cause of death was intermediate lobe pituitary tumors and that the vast majority of p107, and p130 in vivo and accounts for the majority of the repressive pocket protein complexes (Moberg et al., 1996) . E2F5
the Rb ϩ/Ϫ animals (23/27) also displayed c-cell thyroid tumors (Figures 1A and 1B ; data not shown). Mutation of a single E2f4 is expressed in G 0 cells and is primarily regulated by p130 (Hijmans et al., 1995; Sardet et al., 1995) . ChIP assays confirm allele did not significantly alter the lifespan of Rb ϩ/Ϫ animals ( Figure 1A ). Moreover, the Rb ϩ/Ϫ ;E2f4 ϩ/Ϫ mice developed pituthat E2F4, p107, p130, and HDAC specifically associate with E2F-responsive promoters in G 0 /G 1 cells under physiological itary (55/57) and thyroid (47/57) tumors that were comparable to those arising in the Rb ϩ/Ϫ controls with respect to both inciconditions (Rayman et al., 2002; Takahashi et al., 2000) . Importantly, MEFs deficient for E2F4 and E2F5 are unable to arrest dence and size ( Figure 1B ; data not shown). Thus, a reduction in the levels of E2F4 had no notable effect on tumorigenicity in in G 1 in response to a variety of growth arrest signals, suggesting that the repressive E2Fs promote cell cycle arrest (Gaubatz et the Rb mutant mice. Remarkably, the phenotype of Rb ϩ/Ϫ ;E2f4 Ϫ/Ϫ animals dial., 2000) .
Considerable attention has focused on understanding how verged considerably from those of their littermate controls. First, there was a significant difference (p ϭ 0.0033) in lifespan of the the growth-suppressive properties of pRB relate to its role in the inhibition of the activating E2Fs versus its participation in Rb ϩ/Ϫ ;E2f4 Ϫ/Ϫ versus the Rb ϩ/Ϫ animals ( Figure 1A ; Table 1 ). Two of the Rb ϩ/Ϫ ;E2f4 Ϫ/Ϫ mice died at early ages (2.7 and 5.4 months) repressive pRB-E2F complexes. The analysis of Rb;E2f1 and Rb;E2f3 compound mutant mice has shown that the absence as a result of an increased susceptibility to infections. This is a characteristic phenotype of the E2f4 Ϫ/Ϫ mice and was therefore of E2F1 or E2F3 is sufficient to suppress both the ectopic S phase entry and p53-dependent apoptosis arising in pRB-defian anticipated outcome for a fraction of the Rb ϩ/Ϫ ;E2f4 Ϫ/Ϫ mice. However, we unexpectedly found that neither of these animals cient embryos (Tsai et al., 1998; Ziebold et al., 2001) . Moreover, E2F1 deficiency significantly diminishes the development of tuhad any evidence of tumorigenic lesions (data not shown), even though such lesions are routinely observed in the pituitaries of mors in Rb ϩ/Ϫ mice (Yamasaki et al., 1998) . These data suggest that the inappropriate release of the activator E2Fs makes a Rb ϩ/Ϫ mice by 3 months of age (Nikitin and Lee, 1996) . Most importantly, the majority of the Rb ϩ/Ϫ ;E2f4 Ϫ/Ϫ mice (17/19) sursignificant contribution to the phenotypic consequences of pRB deficiency. However, these experiments do not rule out a role vived at least until the window of lethality of the Rb ϩ/Ϫ littermate Rb ϩ/Ϫ ;E2f4 Ϫ/Ϫ mice displayed any evidence of pituitary tumors, although they were detected in some of the older Rb ϩ/Ϫ ;E2f4 Ϫ/Ϫ mice (Table 1) . However, the incidence of pituitary tumors was significantly lower than in the Rb ϩ/Ϫ controls (p ϭ 0.000092), and there was a considerable range in size in the tumors that did arise in the Rb ϩ/Ϫ ;E2f4 Ϫ/Ϫ animals ( Table 1 ; Figure 1B ; data not shown). Three of the older Rb ϩ/Ϫ ;E2f4 Ϫ/Ϫ animals (16.2, 20.5, and 23 months) eventually developed tumors comparable to those seen in the Rb ϩ/Ϫ mice (8.5-13.9 months), but others developed very early lesions or mid-sized tumors (16.5 and 26.6 months), and two animals had completely normal pituitaries (18.2 and 18.5 months).
E2F4 loss had an even greater effect on the development of thyroid tumors in Rb ϩ/Ϫ mice (p ϭ 0.00000034). Despite the extremely high incidence of c-cell thyroid tumors in the Rb ϩ/Ϫ (23/27) and Rb ϩ/Ϫ
;E2f4
ϩ/Ϫ (47/57) animals, only 1/17 of the Rb ϩ/Ϫ ;E2f4 Ϫ/Ϫ mice developed a thyroid tumor (Table 1 ; data not shown). Indeed, there was no evidence of thyroid hyperplasia in the remaining 16/17 Rb ϩ/Ϫ ;E2f4 Ϫ/Ϫ animals. Thus, we conclude that the absence of E2F4 dramatically suppresses the development of both pituitary and thyroid tumors in the Rb ϩ/Ϫ mice and thereby greatly extends their lifespan.
Loss of E2F4 induces profound rearrangement of E2F-pocket protein complexes
We initiated the tumor studies with the expectation that E2F4 loss would either have no effect on or would exacerbate the formation of pRB-deficient tumors depending on whether or not the repressive E2F-pocket protein complexes were important for tumor suppression. Instead, our data clearly show that E2F4 loss inhibits the formation of tumors. To establish the underlying mechanism, we characterized the effect that E2F4 loss had on the remaining E2F-pocket protein complexes. Initially, we compared the E2F complexes present in extracts from wildtype, Rb Figure S1C at http://www.cancercell.org/cgi/content/full/2/6/ 463/DC1; data not shown). Thus, E2F4 loss allows p107 and p130 to substitute for pRB by binding E2F1 and E2F3.
Since the activating E2Fs are known to be important downcontrols (8.5-13.9 months). Moreover, 4 months after the death stream targets of the pRB tumor suppressor, the formation of of the oldest surviving Rb ϩ/Ϫ animal, half of the Rb ;E2f4 Ϫ/Ϫ animals lived to an age (20-27 months) mice. To address this issue, we used electrophoretic mobility comparable to wild-type controls ( Figure 1A ; Table 1 ). Thus, the shift assays to establish whether these novel complexes were absence of E2F4 actually extended the lifespan of the Rb
Ϫ/Ϫ tissues. For these experiments, we mice.
immunoprecipitated p107 from extracts derived from several Consistent with the prolonged lifespan, E2F4 loss greatly tissues, including the pituitary, which is prone to tumors in Rb ϩ/Ϫ suppressed the formation of tumors in the Rb ϩ/Ϫ mice (Table  animals . The associated E2F species were released by the addi-1). Histological examination showed that the vast majority of tion of the detergent deoxycholate (DOC) and then identified in the Rb ϩ/Ϫ ;E2f4 Ϫ/Ϫ animals died as a result of defects typical of electrophoretic mobility shift assays (Figure 3) . Regardless of the tissue examined, p107 associated specifically with E2F4 in the E2f4 Ϫ/Ϫ mice. Indeed, prior to 16 months of age, none of the the wild-type and Rb ϩ/Ϫ mutant mice ( Figures 3A, 3B , and 3D). 4A). DOC release and electrophoretic mobility shift assays confirmed that E2F4 and E2F5 accounted for all of the p107-and In contrast, p107 bound at least three distinct E2F complexes p130-associated E2F activity in wild-type cells ( Figure 4A ). In in the tissues derived from the Rb ϩ/Ϫ ;E2f4 cies, and the other E2F complexes were completely retarded MEFs were unaffected by anti-E2F4 and anti-E2F5 antibodies. by a combination of antibodies against E2F1 and E2F3. E2F1
The remaining complexes corresponded to E2F1, E2F3a, and and E2F5 were also observed when the immunoprecipitations E2F3b (data not shown). Importantly, we found that the specwere conducted with anti-p130 antibodies (data not shown).
trum of E2F complexes in the Rb Ϫ/Ϫ MEFs was a composite of Thus, the absence of E2F4 enables p107 and p130 to bind those of the wild-type and Rb 
;E2f4
Ϫ/Ϫ animals both die in utero (reviewed by Mulli-E2F5 ( Figure 4A and see below). gan and Jacks, 1998; E.Y.L. and J.A.L., unpublished observaThis analysis raised the possibility that p107 and p130 might tions), these experiments were conducted using MEFs (Figure act in pRB-deficient cells to bind to E2F1 and E2F3 even in the presence of physiological levels of E2F4. To further test this hypothesis, we examined the pocket protein binding properties of E2F1 and E2F3 in Rb Ϫ/Ϫ and Rb
Ϫ/Ϫ
;E2f4 Ϫ/Ϫ MEFs by immunoprecipitating the activator E2Fs and Western blotting for associated pocket proteins ( Figure 4B ). These experiments confirmed that there was a robust association between the activating E2Fs and p107 and p130 in Rb Ϫ/Ϫ cells. Furthermore, the absence of both E2F4 and pRB strikingly increased the level of E2F1-associated p130 when compared to Rb Ϫ/Ϫ cells. Taken together, these data yield two important conclusions. First, in pRB-deficient cells, p107 and p130 appear to substitute for pRB in the regulation of the activating E2Fs. Second, E2F4 loss enhances the formation of these novel complexes, presumably by increasing the levels of the free pools of p107 and p130. lacking both pRB and E2F4 resulted from the reassortment of complexes such that p107/p130 associated with activating pression of known E2F-responsive genes, cyclin E and p107 (Herrera et al., 1996; Hurford et al., 1997) . Given the apparent E2Fs. Given these findings, we investigated whether loss of E2F4 had an impact on the proliferative capacity of Rb-deficient rescue of the Rb Ϫ/Ϫ proliferation defect in Rb
Loss of E2F4 suppresses inappropriate E2F target gene expression and cell proliferation
;E2f4 Ϫ/Ϫ MEFs, we hypothesized that the loss of E2F4 might also modulate MEFs. To address this issue, we compared the levels of proliferation in wild-type, Rb 
;E2f4
Ϫ/Ϫ MEFs grown to conthe expression of E2F-responsive genes. We investigated this possibility by examining expression of the cyclin E gene in wildfluence. Wild-type cells incorporated BrdU at low levels, as expected for a quiescent population (Figures 5A and 5B) . In type, Rb
, and Rb
Ϫ/Ϫ
;E2f4 Ϫ/Ϫ MEFs grown to confluence. As expected from previous studies (Herrera et al., 1996 ; Hurford contrast, Rb Ϫ/Ϫ cells largely failed to arrest in response to confluent growth, and approximately 40% of the cells entered S et al., 1997), cyclin E was expressed at very low levels in confluent, wild-type cells but was markedly elevated in cells deficient phase. Remarkably, loss of E2f4 completely suppressed this inappropriate proliferation and restored the low levels of BrdU for Rb ( Figure 5C ). In striking contrast, cyclin E RNA levels were dramatically and consistently reduced in cells deficient for both incorporation observed in wild-type cells.
The abnormal proliferation observed in confluent Rb
Rb and E2f4 to levels that approximated those observed in wildtype cells. We demonstrated that each of these effects was MEFs has been shown to correlate with the inappropriate ex- 
MEFs and enhanced by further loss of E2F4
A-B: MEFs were lysed with ELB buffer and were subjected to immunoprecipitation, DOC release, and EMSA with p107 or p130 antibodies (A) or were immunoprecipitated with anti-E2F1 or anti-E2F3 antibodies and Western blotted with pocket protein antibodies (B). Specific E2F-DNA complexes in the absence of antibody retardation are indicated.
specific, since expression of a second E2F target gene, B-myb, pressive properties of pRB. Since E2F4 cooperates with the pocket known to be under the control of p107/p130 but not pRB (Hurproteins in gene repression, we anticipated that E2F4 loss would ford et al., 1997; Rayman et al., 2002) , was not affected by either exacerbate or have no effect on the tumor phenotype of mutation of Rb or Rb and E2f4 ( Figure 5C ; data not shown).
the Rb ϩ/Ϫ mice depending upon whether or not repression was To extend these findings, we performed Western blotting on important. Instead, we found that the absence of E2F4 greatly extracts derived from wild-type and mutant MEFs and examined inhibited the formation of both pituitary and thyroid tumors, expression of several E2F target genes. These experiments conenabling a significant fraction of the Rb ϩ/Ϫ ;E2f4 Ϫ/Ϫ mice to live firmed our RT-PCR studies and showed that expression of cyclin as long as wild-type controls. Indeed, the degree of tumor sup-E and a second established pRB target, p107, was markedly pression significantly exceeded that resulting from the loss of elevated in Rb-deficient cells. Furthermore, simultaneous loss the activating E2Fs, E2F1 or E2F3, in an Rb ϩ/Ϫ background of E2f4 largely reversed this deregulation in two independent (Yamasaki et al., 1998 ; U.Z. and J.A.L., unpublished observapreparations of doubly null MEFs ( Figure 5D ). These findings tions). Furthermore, we demonstrated that loss of E2f4 in Rbstrongly suggest that loss of E2f4 suppresses tumorigenic deficient cells restored the control of E2F-responsive genes growth of Rb-deficient cells by restoring both appropriate levels and the inhibition of DNA synthesis characteristic of wild-type, of expression of critical E2F target genes and a normal response confluence-arrested cells. Since the loss of contact inhibition to cues that limit cell proliferation.
is one of the hallmarks of a cancer cell, we suggest that this finding could explain the tumor suppression we observe in pituDiscussion itaries and thyroids of Rb ϩ/Ϫ ;E2f4 Ϫ/Ϫ mice. Thus, this study provides direct evidence for a critical role of E2F4 in pRB function. The goal of these studies was to establish whether the formation of repressive E2F complexes contributes to the tumor-sup-E2F4 loss could be exerting its tumor-suppressive effects via several possible mechanisms. The simplest model is that specifically occupies E2F-responsive promoters in association with p107 and p130 during the G 0 /G 1 stages of the cell cycle E2F4 contributes to the activation of E2F-responsive genes and is therefore a key downstream target of pRB in a similar manner when these targets are transcriptionally repressed (Rayman et al., 2002; Takahashi et al., 2000) . Finally, primary cells that are to E2F1 and E2F3. This conclusion is supported by early studies that showed that E2F4 has significant transcriptional activity in deficient for E2F4 and E2F5 are defective in cell cycle arrest but not proliferative functions (Gaubatz et al., 2000) . Clearly, overexpression experiments (Beijersbergen et al., 1994; Ginsberg et al., 1994) . However, analysis of the endogenous E2F4 these data do not rule out the possibility that E2F4 could contribute to the activation of E2F-responsive genes in pRB-deficient protein does not support this conclusion. First, the predominant cytoplasmic localization of the free E2F4-DP complexes is intumor cells, and experiments that investigate both expression profiles and promoter occupancy of target genes will be needed consistent with their role in transcriptional activation (Gaubatz et al., 2001; Magae et al., 1996; Muller et al., 1997; to address this issue further. Moreover, it is important to note that although it is widely assumed that E2F1 and E2F3 contribute al., 1997). Second, ChIP assays strongly suggest that E2F4 to the formation of tumors through this mechanism, this has not yet been demonstrated. Therefore, experiments with Rb;E2f compound mutant cells will be critical in testing this hypothesis as well.
An alternative model arising from our data suggests that E2F4 loss could increase the apoptotic potential of pRB-deficient cells. Under these conditions, cells in the Rb ϩ/Ϫ ;E2f4 Ϫ/Ϫ mice that lose the wild-type Rb allele might be eliminated by apoptosis rather than become tumorigenic. This is a reasonable concern because there is considerable evidence supporting a role for the E2F proteins in the regulation of many apoptosis genes (reviewed by Trimarchi and Lees, 2002 
;E2f4
Ϫ/Ϫ ES cell lines that can be used to generate chimeric mutant mice. Such mutant animals will be invaluable because they will allow us to establish whether Rb Ϫ/Ϫ
Ϫ/Ϫ cells can contribute to adult tissues. Since it is well established that the formation of tumors in Rb ϩ/Ϫ mice depends upon the inactivation of the wild-type Rb allele, it is also possible that the rearrangement in pocket protein complexes in the Rb ϩ/Ϫ ;E2f4 Ϫ/Ϫ tissues somehow diminishes the selective pressure for loss of heterozygosity. In addition, our data do not rule out the possibility that the observed tumor-suppressive effect of E2F4 loss is cell non-autonomous. Thus, the generation of both conditional and chimeric mice will also be essential in allowing us to address these two issues.
A final model suggests that E2F4 loss suppresses tumors by simply altering the spectrum of the remaining E2F complexes. We currently favor this hypothesis, based on our biochemical analysis. Specifically, our data show that E2F4 loss promotes , 1998; Ziebold et al., 2001) . We therefore propose results in the association of p107 and p130 with the activator E2Fs, conferring that E2F4 loss suppresses tumorigenesis by increasing the free tumor-suppressive functions on p107 and p130. Loss of pRB alone also promotes some binding of p107 and p130 to E2F1 and E2F3. Thus, the levels of pools of p107 and p130 and thereby enabling them to substitute available p107 and p130 in individual tissues may account for the tissue for pRB in the inhibition of the activating E2Fs ( Figure 6 ). This specificity of Rb Ϫ/Ϫ tumor formation.
could also account for the observed suppression of inappropriate E2F-responsive gene expression and cell cycle entry of confluence-arrested Rb Ϫ/Ϫ MEFs ( Figures 5B and 5C ). Additional tumor studies will be required to distinguish between these 2000; Robanus-Maandag et al., 1998 ; Sage et models. However, regardless of the precise mechanism by al., 2000). Specifically, pRB is a classical tumor suppressor, but which E2F4 loss is operating, our studies do not provide any mutation of p107 and/or p130 promotes tumor formation only support for a role of repressive E2F-pocket protein complexes when pRB is also inactivated. We believe that our observations in tumor suppression. Instead, they strongly suggest that the can account for these differential properties. First, we propose critical tumor suppressive role of pRB is to inhibit E2F family that tumor formation is dependent upon the inappropriate remembers that mediate the activation of E2F-responsive genes.
lease of the activating E2Fs. Since these E2Fs are specifically Importantly, we also detected p130-E2F1 and p107-E2F3 regulated by pRB in normal cells, their release can only be complexes in cells that had physiological levels of E2F4, but triggered by the loss of pRB and not p107 and/or p130, exlacked the pRB tumor suppressor. Since the generation of Rb Ϫ/Ϫ plaining why pRB is the key tumor suppressor in vivo. Second, cells is a key step in the development of many naturally occurring our data suggest that pRB loss causes p107 and p130 to substitumors, we believe that the formation of novel E2F-pocket protute for pRB in the regulation of the activating E2Fs. In this tein complexes has significant in vivo relevance. There is extenmanner, p107 and p130 become significant tumor suppressive evidence from both human tumors and mutant mouse modsors in pRB-deficient cells. Consistent with this hypothesis, els that the pocket proteins play non-overlapping roles in the Rb tracts from day 2 confluent MEFs were prepared as previously described
It is important to note that mutation of p107 and/or p130 is (Moberg et al., 1996) , and Western blotting was performed using anti-cyclin not required for the formation of most pRB-deficient tumors.
E (sc-481), anti-p107 (sc-318) (each from Santa Cruz Biotech), and antiWe must therefore conclude that p107 and p130 are unable to ␤-tubulin (T-4026, Sigma) antibodies. RT-PCR assays were carried out as compensate for the loss of pRB in tumor-prone tissues. Inheridescribed in Ren et al. (2002) using an Invitrogen RT-PCR Superscript One
Step kit.
tance of germline Rb mutations results in a highly tissue-specific tumor spectrum in both humans (retinoblastoma) and mice (pituAcknowledgments itary and thyroid tumors). Since pRB is believed to play a key role in all tissue types, the underlying basis for this tissueWe thank R. Bronson and A. Caron for generation and analysis of histological specific spectrum is not understood. We believe that our obsersections and T. Jacks for providing Rb mutant mice and protocols for tissue extraction. We are grateful to R. Weinberg, T. Jacks, and J. Sage for helpful vations could also explain this phenomenon. Our data show comments. This work was supported by grants from the American Cancer that the absence of E2F4 increases the levels of p107 and tissues may simply be those where the levels of available p107 and p130 are insufficient to substitute fully for pRB in the inhibition of the activating E2Fs ( Figure 6 ). By extension of this logic, a relatively modest increase in the free pools of p107 and p130 may be sufficient to prevent the formation of tumors. This sug-
